Lasofoxifene
Also known as: Fablyn, CP-336156, Lasofoxifene tartrate, Oporia
Classification
Serm
Regulatory Status
not-established
Sources
6
Review
n/a
Overview
Lasofoxifene is a nonsteroidal, third-generation selective estrogen receptor modulator that binds both ERα and ERβ with high affinity, acting as an estrogen-receptor antagonist in breast and endometrial tissue while producing estrogen-agonist effects in bone.
Evidence and limitations
Human/preclinical evidence breakdown is not available in this record.
Pathways
Lasofoxifene is a nonsteroidal, third-generation selective estrogen receptor modulator that binds both ERα and ERβ with high affinity, acting as an estrogen-receptor antagonist in breast and endometrial tissue while producing estrogen-agonist effects in bone.
Interactions & cautions
Drug interactions
systemic estrogens or other SERMs/aromatase inhibitors without oncology supervision — Antagonistic or complex endocrine effects (review)
These are observational flags for review, not individualized instructions.
Sources
Educational reference only — not medical advice.
What people report (anecdote)
CLINICAL DATA (from trials)
Adverse events:
None recorded in our sources.
Effects measured:
Human trials: none found.
ANECDOTE
What people report: anecdote, not evidence
Loading…
Submit a claim you saw